American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
MORRISTOWN, N.J., Feb. 22, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2017, after the market close on Thursday, March 8, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, March 8 | |
| Time: | 4:30 PM ET | |
| Toll free (U.S.): | 888-882-4478 | |
| International: | 323-794-2149 | |
| Conference ID: | 4931261 | |
| Webcast: | http://public.viavid.com/index.php?id=128364 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
